Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRenJi Hospital
About this trial
This study aims to establish an ambispective cohort platform centered on the pathological axis of "sarcopenia-metabolic disorders-aging progression", integrating multimodal data including demographic characteristics, lifestyle factors, clinical phenotypes, laboratory tests, medical imaging, and biospecimens. Namely 'Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)'.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
Does not cooperate in signing the informed consent form;
Does not possess legal capacity;
In a state of loss of consciousness;
Suffering from severe mental illness, unable to communicate normally;
Trial population
Patients visiting the Geriatrics Department of Renji Hospital affiliated with Shanghai Jiao Tong University School of Medicine, who were aged 18 years and above.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
nothing
Other interventionThis is an observational study.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
all-cause mortality
Collect information on all-cause mortality of patients through hospital medical records, telephone follow-ups, outpatient follow-ups, etc., in order to assess the combined effects and underlying mechanisms of sarcopenia, metabolic diseases, and aging on all-cause mortality.
Time frame
From enrollment to the 5-year and 10-year follow-up visit.Secondary outcomes
1
cause-specific mortality
Collect information on cause-specific mortality of patients through hospital medical records, telephone follow-ups, outpatient follow-ups, etc., in order to assess the combined effects and underlying mechanisms of sarcopenia, metabolic diseases, and aging on cause-specific mortality. In-depth exploration of the role of sarcopenia, metabolic diseases, and aging in the severe outcomes of mortality caused by various diseases.
Time frame
At 5 and 10 years from the baseline visit.2
Major adverse cardiovascular events
Through medical records within the hospital, telephone follow-ups, outpatient follow-ups, we will collect detailed information on the occurrence of new major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke) in the study subjects during the follow-up period. The aim is to analyze the impact, mechanisms, and interactions of sarcopenia, metabolic diseases, and aging on the occurrence and development of these adverse events.
Time frame
At 5 and 10 years from the baseline visit.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov